Skip to content
Menu

Kailera Therapeutics, Inc. KLRA

Full chart Compare
Set alert

Price alert · KLRA

All alert types
12.57 USD -0.70 (-5.28%)

Regular-session close

12.19 -0.38 -3.02%

After hours · Nov 16, 5:17 PM ET

12.47 Day range 13.31
9.76 52-week range 28.23
YTD
-51.65%
1 year
-51.65%
Market cap
1.63B
EPS (ttm)
-4.16
Shares out
129.85M
Forward P/E
-3.14
YTD return
-51.65%
1-year return
-51.65%
50-day average
12.56
200-day average
17.65
Enterprise value
831.63M
Volume
962.42K
Avg volume
1.11M
Open
12.91
Previous close
13.27
Day's range
12.47 – 13.31
52-week range
9.76 – 28.23
Analysts
Strong Buy
Price target
43.00 (+242.1%)
Earnings date
Mar 3, 2027

 

No chart data for this range yet.

Key statistics

Price / book
1.58
Total cash
901.45M
Total debt
9.97M
Short % of float
6.29%

Fundamental scorecard

3 of 25 checks passed on KLRA’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
KLRA Revenue — quarterly 0
KLRA Net income — quarterly -95.67M
KLRA EPS — quarterly -0.74

Earnings

KLRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 3, 2027Dec 30, 2026-0.9034———
Nov 4, 2026Sep 30, 2026-0.73358-0.74-0.01-0.88%
Aug 12, 2026Jun 30, 2026-0.89667-1.09-0.19-21.56%
May 26, 2026Mar 31, 2026-0.775-3,650.00-3,649.22-470,867.74%

Upgrades / downgrades

KLRA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Canaccord Genuityinit—Buy
May 12, 2026Leerink Partnersinit—Outperform
May 12, 2026Jefferiesinit—Buy
May 12, 2026Evercore ISI Groupinit—Outperform
May 12, 2026JP Morganinit—Overweight

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kailera.com

News

Your note

Sign in to keep a note on KLRA — it syncs with the Stock Master app.

Insider holders

KLRA insider holders
InsiderRelationLatest transactionDateShares held
BAIN CAPITAL INVESTORS, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 19, 20260
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseApr 19, 20260
JIANGSU HENGRUI PHARMACEUTICALS CO. LTD.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 19, 20262,034,130
KAPLAN ANDREW TDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 19, 20260
KOPPEL ADAM MDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 19, 20260
RENAUD RONALD C JRChief Executive OfficerConversion of Exercise of derivative securityJun 8, 202638,094

Institution ownership

KLRA institution ownership
Holder% heldSharesValueReported
Bain Capital Investors Llc20.22%26,255,581330.03MJun 29, 2026
Bain Capital Life Sciences Investors, LLC17.39%22,583,268283.87MJun 29, 2026
RTW Investments LP8.30%10,776,820135.46MJun 29, 2026
Canada Pension Plan Investment Board5.63%7,304,68891.82MJun 29, 2026
Atlas Venture Life Science Advisors, LLC 3.98%5,171,28265.00MSep 29, 2026
FMR, LLC3.59%4,659,88558.57MSep 29, 2026

Fund ownership

KLRA fund ownership
Holder% heldSharesValueReported
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.69%2,191,92827.55MJul 30, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.28%1,657,19920.83MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF0.94%1,221,86915.36MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF0.92%1,199,78315.08MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.91%1,180,41114.84MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.70%904,28311.37MJun 29, 2026